A reduction in Pten tumor suppressor activity promotes ErbB-2-induced mouse prostate adenocarcinoma formation through the activation of signaling cascades downstream of PDK1

American Journal of Pathology

Volumn 174, Issue 6, 2009, Pages 2051-2060

  Rodriguez, Olga C ^a   Lai, Edwin W ^a,c   Vissapragada, Sarada ^a   Cromelin, Caroline ^a   Avetian, Maral ^a   Salinas, Patricia ^a   Ramos, Hida ^a   Kallakury, Bhaskar ^a,b   Casimiro, Mathew ^d   Lisanti, Michael P ^d   Tanowitz, Herbert B ^e   Pacak, Karel ^c   Glazer, Robert I ^a   Avantaggiati, Maria ^a   Albanese, Chris ^a,b  

^a GEORGETOWN UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INITIATION FACTOR 4E BINDING PROTEIN 1; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; S6 KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE REGULATION; CELL STRAIN LNCAP; CONTROLLED STUDY; DNA MODIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

EID: 67049157933     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2009.080859     Document Type: Article

References (36)

1. Shi Y, Chatterjee SJ, Brands FH, Shi SR, Pootrakul L, Taylor CR, Datar R, Cote RJ: Role of coordinated molecular alterations in the development of androgen-independent prostate cancer: an in vitro model that corroborates clinical observations. BJU Int 2006, 97:170-178
2. Dai B, Kong YY, Ye DW, Ma CG, Zhou XY, Yao XD: Human epidermal growth factor receptor type 2 protein expression in Chinese metastatic prostate cancer patients correlates with cancer specific survival and increases after exposure to hormonal therapy. Asian J Androl 2008, 10:701-709
3. Casimiro MC, Rodriguez O, Pootrakul L, Fricke ST, Ostrowski M, Rabbani S, Datar R, Cote RJ, Pestell R, Albanese C: ErbB-2 induces the cyclin D1 gene in prostate epithelial cells in vitro and in vivo. Cancer Res 2007, 67:4364-4372. (Pubitemid 46815085)
4. Cantley LC, Neel BG: New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/ AKT pathway. Proc Natl Acad Sci USA 1999, 96:4240-4245 (Pubitemid 29190320)
5. Whang YE, Wu X, Suzuki H, Reiter RE, Tran C, Vessella RL, Said JW, Isaacs WB, Sawyers CL: Inactivation of the tumor suppressor PTEN/ MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci USA 1998, 95:5246-5250 (Pubitemid 28208583)
6. Di Cristofano A, Pandolfi PP: The multiple roles of PTEN in tumor suppression. Cell 2000, 100:387-390 (Pubitemid 30818176)
7. McMenamin ME, Soung P, Perera S, Kaplan I, Loda M, Sellers WR: Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 1999, 59:4291-4296 (Pubitemid 29418745)
8. Rubin MA, Gerstein A, Reid K, Bostwick DG, Cheng L, Parsons R, Papadopoulos N: 10q23.3 loss of heterozygosity is higher in lymph node-positive (pT2-3,N+) versus lymph node-negative (pT2-3,N0) prostate cancer. Hum Pathol 2000, 31:504-508 (Pubitemid 30262874)
9. Albanese C, Rodriguez O, Johnson MD, Fricke S: Models of prostate cancer. Drug Discov Today: Disease Models 2005, 2:7-13 (Pubitemid 40932053)
10. Di Cristofano A, De Acetis M, Koff A, Cordon-Cardo C, Pandolfi PP: Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat Genet 2001, 27:222-224 (Pubitemid 32157454)
11. Abate-Shen C, Banach-Petrosky WA, Sun X, Economides KD, Desai N, Gregg JP, Borowsky AD, Cardiff RD, Shen MM: Nkx3.1; Pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases. Cancer Res 2003, 63:3886-3890
12. Nardella C, Chen Z, Salmena L, Carracedo A, Alimonti A, Egia A, Carver B, Gerald W, Cordon-Cardo C, Pandolfi PP: Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events. Genes Dev 2008, 22:2172-2177
13. Trotman LC, Niki M, Dotan ZA, Koutcher JA, Cristofano AD, Xiao A, Khoo AS, Roy-Burman P, Greenberg NM, Dyke TV, Cordon-Cardo C, Pandolfi P: Pten dose dictates cancer progression in the prostate. PLoS Biol 2003, 1:E59 (Pubitemid 39112137)
14. Jia S, Liu Z, Zhang S, Liu P, Zhang L, Lee SH, Zhang J, Signoretti S, Loda M, Roberts TM, Zhao JJ: Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature 2008, 454: 776-779
15. Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M, Koutcher JA, Scher HI, Ludwig T, Gerald W, Cordon-Cardo C, Pandolfi PP: Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005, 436:725-730 (Pubitemid 41117277)
16. Zhong C, Saribekyan G, Liao CP, Cohen MB, Roy-Burman P: Cooperation between FGF8b overexpression and PTEN deficiency in prostate tumorigenesis. Cancer Res 2006, 66:2188-2194 (Pubitemid 43294929)
17. Fricke S, Rodriguez O, Vanmeter J, Dettin L, Casimiro M, Chien C, Newell T, Johnson K, Ileva L, Johnson MD, Albanese C: In vivo magnetic resonance volumetric and spectroscopic analysis of mouse prostate cancer models. Prostate 2006, 66:708-717
18. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP: PTEN is essential for embryonic development and tumour suppression. Nat Genet 1998, 19:348-355 (Pubitemid 28357906)
19. Rodriguez O, Fricke S, Chien C, Dettin L, Vanmeter J, Shapiro E, Dai HN, Casimiro M, Ileva L, Dagata J, Johnson MD, Lisanti MP, Koretsky A, Albanese C: Contrast-enhanced in vivo imaging of breast and prostate cancer cells by MRI. Cell Cycle 2006, 5:113-119
20. ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. J Biol Chem 1995, 270:23589-23597
21. Albanese C, D'Amico M, Reutens AT, Fu M, Watanabe G, Lee RJ, Kitsis RN, Henglein B, Avantaggiati M, Somasundaram K, Thimmapaya B, Pestell RG: Activation of the cyclin D1 gene by the E1A-associated protein p300 through AP-1 inhibits cellular apoptosis. J Biol Chem 1999, 274:34186-34195 (Pubitemid 129511756)
22. Albanese C, Wu K, D'Amico M, Jarrett C, Joyce D, Hughes J, Hulit J, Sakamaki T, Fu M, Ben-Ze'ev A, Bromberg JF, Lamberti C, Verma U, Gaynor RB, Byers SW, Pestell RG: IKKalpha regulates mitogenic signaling through transcriptional induction of cyclin D1 via Tcf. Mol Biol Cell 2003, 14:585-599
23. Kwong KY, Hung MC: A novel splice variant of HER2 with increased transformation activity. Mol Carcinog 1998, 23:62-68 (Pubitemid 28507415)
24. Lai EW, Rodriguez OC, Aventian M, Cromelin C, Fricke ST, Martiniova L, Lubensky IA, Lisanti MP, Picard KL, Powers JF, Tischler AS, Pacak K, Albanese C: ErbB-2 induces bilateral adrenal pheochromocytoma formation in mice. Cell Cycle 2007, 6:1946-1950 (Pubitemid 47327914)
25. Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C, Blenis J: mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol 2004, 24:200-216 (Pubitemid 38010048)
26. Kim KK, Lee JJ, Yang Y, You KH, Lee JH: Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of ErbB2 in human breast and gastric cancer cells. Carcinogenesis 2008, 29:704-712
27. Kremer CL, Klein RR, Mendelson J, Browne W, Samadzedeh LK, Vanpatten K, Highstrom L, Pestano GA, Nagle RB: Expression of mTOR signaling pathway markers in prostate cancer progression. Prostate 2006, 66:1203-1212 (Pubitemid 44175342)
28. Armengol G, Rojo F, Castellvi J, Iglesias C, Cuatrecasas M, Pons B, Baselga J, Ramon y Cajal S: 4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications. Cancer Res 2007, 67:7551-7555
29. Klos KS, Wyszomierski SL, Sun M, Tan M, Zhou X, Li P, Yang W, Yin G, Hittelman WN, Yu D: ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/ p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells. Cancer Res 2006, 66:2028-2037 (Pubitemid 43294911)
30. Zhou X, Tan M, Stone Hawthorne V, Klos KS, Lan KH, Yang Y, Yang W, Smith TL, Shi D, Yu D: Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res 2004, 10:6779-6788 (Pubitemid 39383026)
31. Ou CC, Hsu SC, Hsieh YH, Tsou WL, Chuang TC, Liu JY, Kao MC: Downregulation of HER2 by RIG1 involves the PI3K/Akt pathway in ovarian cancer cells. Carcinogenesis 2008, 29:299-306 (Pubitemid 351359668)
32. Averous J, Fonseca BD, Proud CG: Regulation of cyclin D1 expression by mTORC1 signaling requires eukaryotic initiation factor 4E-binding protein 1. Oncogene 2008, 27:1106-1113 (Pubitemid 351253179)
33. MacManus CF, Pettigrew J, Seaton A, Wilson C, Maxwell PJ, Berlingeri S, Purcell C, McGurk M, Johnston PG, Waugh DJ: Interleukin-8 signaling promotes translational regulation of cyclin D in androgen-independent prostate cancer cells. Mol Cancer Res 2007, 5:737-748
34. Gera JF, Mellinghoff IK, Shi Y, Rettig MB, Tran C, Hsu JH, Sawyers CL, Lichtenstein AK: AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem 2004, 279:2737-2746 (Pubitemid 38114263)
35. Kinkade CW, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, Gao H, Sun Y, Ouyang X, Gerald WL, Cordon-Cardo C, Abate-Shen C: Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest 2008, 118:3051-3064
36. De Benedetti A, Graff JR: eIF-4E expression and its role in malignancies and metastases. Oncogene 2004, 23:3189-3199 (Pubitemid 38638830)